Biomarker-Driven Drug Development Market - Strategic Insights and Forecasts (2026-2031)

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

1. 2.1. Market Overview

2. 2.2. Market Definition

3. 2.3. Scope of the Study

4. 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

1. 3.1. Market Drivers

2. 3.2. Market Restraints

3. 3.3. Market Opportunities

4. 3.4. Porter’s Five Forces Analysis

5. 3.5. Industry Value Chain Analysis

6. 3.6. Policies and Regulations

7. 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. BIOMARKER-DRIVEN DRUG DEVELOPMENT MARKET BY BIOMARKER TYPE

1. 5.1. Introduction

2. 5.2. Genomic Biomarkers

3. 5.3. Proteomic Biomarkers

4. 5.4. Metabolomic Biomarkers

5. 5.5. Epigenetic Biomarkers

6. 5.6. Transcriptomic Biomarkers

6. BIOMARKER-DRIVEN DRUG DEVELOPMENT MARKET BY TECHNOLOGY

1. 6.1. Introduction

2. 6.2. Next-Generation Sequencing (NGS)

3. 6.3. Polymerase Chain Reaction (PCR)

4. 6.4. Immunoassays

5. 6.5. Mass Spectrometry

6. 6.6. Microarray Technology

7. 6.7. Digital Pathology

8. 6.8. Others

7. BIOMARKER-DRIVEN DRUG DEVELOPMENT MARKET BY APPLICATION

1. 7.1. Introduction

2. 7.2. Oncology

3. 7.3. Cardiovascular Diseases

4. 7.4. Neurological Disorders

5. 7.5. Infectious Diseases

6. 7.6. Autoimmune Diseases

7. 7.7. Metabolic Disorders

8. 7.8. Others

8. BIOMARKER-DRIVEN DRUG DEVELOPMENT MARKET BY GEOGRAPHY

1. 8.1. Introduction

2. 8.2. North America

   1. 8.2.1. USA

   2. 8.2.2. Canada

   3. 8.2.3. Mexico

3. 8.3. South America

   1. 8.3.1. Brazil

   2. 8.3.2. Argentina

   3. 8.3.3. Others

4. 8.4. Europe

   1. 8.4.1. United Kingdom

   2. 8.4.2. Germany

   3. 8.4.3. France

   4. 8.4.4. Spain

   5. 8.4.5. Others

5. 8.5. Middle East and Africa

   1. 8.5.1. Saudi Arabia

   2. 8.5.2. UAE

   3. 8.5.3. Others

6. 8.6. Asia Pacific

   1. 8.6.1. China

   2. 8.6.2. India

   3. 8.6.3. Japan

   4. 8.6.4. South Korea

   5. 8.6.5. Indonesia

   6. 8.6.6. Thailand

   7. 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

1. 9.1. Major Players and Strategy Analysis

2. 9.2. Market Share Analysis

3. 9.3. Mergers, Acquisitions, Agreements, and Collaborations

4. 9.4. Competitive Dashboard

10. COMPANY PROFILES

1. 10.1. F. Hoffmann-La Roche Ltd.

2. 10.2. Novartis AG

3. 10.3. Pfizer Inc.

4. 10.4. Merck & Co., Inc.

5. 10.5. AstraZeneca plc

6. 10.6. Bristol-Myers Squibb Company

7. 10.7. AbbVie Inc.

8. 10.8. Amgen Inc.

9. 10.9. Eli Lilly and Company

10. 10.10. Gilead Sciences, Inc.

11. APPENDIX

1. 11.1. Currency

2. 11.2. Assumptions

3. 11.3. Base and Forecast Years Timeline

4. 11.4. Key benefits for the stakeholders

5. 11.5. Research Methodology

6. 11.6. Abbreviations